Fish oil is one of the best-selling supplements in the world, and the case for it looked strong for a long time. Populations eating a lot of oily fish have less heart disease. Omega-3 fatty acids are structurally central to cell membranes and to the brain. The mechanism is plausible and the observational data pointed the right way.
Then the large randomised trials arrived, and the picture became considerably more complicated than the bottle suggests.
What omega-3 actually is
Three fatty acids get grouped under one label, and they are not interchangeable.
EPA and DHA come from marine sources — oily fish and algae. These are the forms the body uses directly, and the ones the research is about.
ALA comes from plants: flaxseed, walnuts, rapeseed, chia. The body converts it into EPA and DHA, but inefficiently — conversion rates to DHA in particular are low, often quoted in the low single-digit percentages. A supplement or food described as omega-3 but supplying only ALA is not equivalent to fish oil, and labels do not always make this obvious.
The trial that changed the conversation
VITAL randomised 25,871 initially healthy US adults to 1 g daily of marine omega-3 (EPA plus DHA) or placebo, alongside a parallel vitamin D comparison, with a median treatment period of 5.3 years.
The primary cardiovascular endpoint — a composite of heart attack, stroke and cardiovascular death — was not significantly reduced. Neither was total invasive cancer.
That is the headline, and it deserves to be stated first because the secondary findings have been reported far more enthusiastically than the primary ones.
Those secondary findings: total heart attacks were reduced by 28%, with reductions also seen in fatal heart attack and in total coronary heart disease. A separate trial, ASCEND, in people with diabetes, also found no benefit on its primary vascular endpoint.
The subgroup result is the interesting one. Among participants eating less than 1.5 servings of fish a week, omega-3 supplementation was associated with a 19% reduction in major cardiovascular events and a 40% reduction in heart attack. Among those already eating more fish than that, there was no protection — and a suggestive increase in cancer risk that the investigators themselves cautioned may have been chance.
Subgroup analyses are the weakest form of evidence a trial produces. Enough subgroups, and some will show effects by chance alone. But this particular one has a coherent story behind it: supplementing a nutrient helps people who are short of it, and does little for people who are not.
Why the observational data pointed the other way
The gap between “populations eating fish have less heart disease” and “fish oil capsules do not prevent heart disease in trials” is the most instructive part of this story.
Three explanations, probably all partly true.
Fish is not fish oil. Eating salmon delivers protein, selenium, iodine, vitamin D and a displacement effect — the meal you ate instead of something else. A capsule delivers two fatty acids.
Fish eaters differ from non-fish eaters. Higher income, more varied diets, different smoking rates. Cohort studies adjust for what they can measure.
Trials mostly recruit well-nourished people on modern medication. If most participants already have adequate omega-3 status, and are taking statins and blood pressure treatment, the room for an additional intervention to show an effect is small. This is a general problem with supplement trials, and it is the strongest argument that null results should not be read as “this nutrient does not matter.”
Where the evidence is stronger
Two areas stand apart from the general disappointment.
High-dose prescription EPA in specific patients. The REDUCE-IT trial used 4 g daily of icosapent ethyl — a purified EPA formulation, at four times the usual supplement dose — in people with elevated triglycerides already on statins, and found a significant reduction in cardiovascular events. This is a prescription medicine used in a defined patient group, not a case for buying fish oil off a shelf.
Triglycerides. Omega-3 at higher doses reliably lowers triglycerides. That effect is not in dispute; what remains debated is how much the reduction translates into fewer events.
Claims around cognition, mood, joint pain and eye health are weaker. There are positive trials in each area and a larger number of null or mixed ones, and none has the weight behind it that the cardiovascular question has received.
The atrial fibrillation signal
One finding that supplement marketing does not mention: several trials and meta-analyses have reported an increased risk of atrial fibrillation with omega-3 supplementation, appearing more pronounced at higher doses.
The absolute risk is small, and for someone with high triglycerides on a prescription regimen the balance may still favour treatment. But it undercuts the assumption that fish oil is a free bet — that even if it does nothing, it cannot hurt. Something with a real physiological effect generally has effects in more than one direction.
What to do
Eat fish. Two portions a week, one of them oily, is the standard advice and it comes with better evidence than any capsule. Salmon, mackerel, sardines, herring, trout. Tinned sardines and mackerel are cheap and count.
If you rarely eat fish, a supplement is reasonable. This is the one group where the trial data offers something — the low-fish-intake subgroup is exactly the population where supplementation looked useful. Look for combined EPA plus DHA content rather than total fish oil weight; a 1,000 mg capsule often contains only 300 mg of the actual actives.
If you eat fish regularly, the case is weak. VITAL found no benefit in that group.
Plant-based eaters should look at algae oil. It supplies EPA and DHA directly, without relying on poor conversion from ALA.
High doses belong with a doctor. Anything approaching prescription territory, particularly if you have a heart rhythm condition or take anticoagulants, should be a medical decision.
The pattern, again
Omega-3 tells the same story as vitamin D, and it is worth noticing because it will keep repeating.
A nutrient is genuinely necessary. Populations short of it do worse. Observational studies show associations across many diseases. A supplement industry grows. Then large randomised trials test the specific claim in well-nourished populations and find far less than the enthusiasm implied.
The nutrient still matters. Correcting a shortfall is worthwhile. What does not follow is that more of it in someone who already has enough will extend their life — and that unearned step is where most of the longevity supplement market lives.
This article is for general information and is not medical advice. If you take anticoagulants, have a heart rhythm condition, or are considering high-dose omega-3, speak to your GP.
Sources
- Manson JE, Cook NR, Lee I-M, et al. Marine n−3 fatty acids and prevention of cardiovascular disease and cancer. New England Journal of Medicine, 2019;380:23–32. https://www.nejm.org/doi/full/10.1056/NEJMoa1811403
- VITAL study findings summary, including fish-intake subgroup results. https://www.vitalstudy.org/findings.html
- ASCEND Study Collaborative Group. Effects of n−3 fatty acid supplements in diabetes mellitus. New England Journal of Medicine, 2018.
- Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia (REDUCE-IT). New England Journal of Medicine, 2019;380:11–22.
- TCTMD. VITAL: no benefits to vitamin D and omega-3s in reducing major CV events, cancer, 2018. https://www.tctmd.com/news/vital-no-benefits-vitamin-d-and-omega-3s-reducing-major-cv-events-cancer
This article is for general information and is not medical advice. If a health problem is affecting your daily life, speak to your GP.
Comments
We read every comment. Be kind, stay on topic, and please don't ask for medical advice — we can't give it.